The capital raise provides near-term funding for operations, but traders should monitor whether the company can achieve milestones that justify further investment. The low liquidity of the warrants may limit their market impact.
Price Chart
Executive Summary
Acurx Pharmaceuticals raised $2.5 million through a registered direct offering of common stock and pre-funded warrants, accompanied by a concurrent private placement of short-term warrants that could bring in an additional $4.6 million if fully exercised. The capital is intended for working capital and general corporate purposes.
Key Financial Metrics
Key Facts
- Raised $2.5 million through sale of 816,068 shares of common stock at $3.03 per share
- Issued pre-funded warrants to purchase up to 9,017 shares of common stock at $3.029 per warrant
- Concurrent private placement of Series H warrants to purchase up to 1,650,170 shares at $2.78 per share, potentially raising $4.6 million if fully exercised
- Proceeds will be used for working capital and general corporate purposes
- H.C. Wainwright & Co. acted as exclusive placement agent, receiving 6% of gross proceeds
Financial Impact
$2.5 million raised upfront with potential for additional $4.6 million from warrant exercises
Risk Factors
- Dilution from the issuance of new shares and potential warrant exercises
- Low liquidity of the pre-funded and Series H warrants
- No assurance that the short-term warrants will be exercised
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-044093 |
| Document: tm2611957d1_ex4-2.htm | 0001104659-26-044093 |
| Document: tm2611957d1_ex4-1.htm | 0001104659-26-044093 |
| Document: tm2611957d1_8k.htm | 0001104659-26-044093 |
| Document: tm2611957d1_ex5-1.htm | 0001104659-26-044093 |
| Document: tm2611957d1_ex99-1.htm | 0001104659-26-044093 |
| Document: 0001104659-26-044093-index-headers.html | 0001104659-26-044093 |
| Document: 0001104659-26-044093-index.html | 0001104659-26-044093 |
| Document: 0001104659-26-044093.txt | 0001104659-26-044093 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 18, 2026 5w ago | EFFECT | $1.39 $1.10 | ▲ +20.86% | ▲ +21.07% | $1.09 (+21.59%) |
Aug 14, 2026 10w ago | Press Release | $1.40 $1.39 | ▼ −0.36% | ▲ +1.63% | $1.09 (−21.87%) |
May 4, 2026 24w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.09 (+45.50%) |
May 4, 2026 24w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.09 (+45.50%) |
Apr 16, 2026 27w ago | 8-K | $2.49 $1.99 | ▼ −20.08% | ▼ −25.90% | $1.09 (−56.23%) |
Apr 16, 2026 27w ago | 424B5 | $2.49 $1.99 | ▲ +20.08% | ▲ +25.90% | $1.09 (+56.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers